Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2005-09-15
2008-09-09
Angell, J. E. (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S006120, C435S325000, C435S375000, C536S023100, C536S024300
Reexamination Certificate
active
07423142
ABSTRACT:
The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an anti-apoptotic gene, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of an apoptotic gene, such as a Bcl gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of an anti-apoptotic gene using the pharmaceutical composition; and methods for inhibiting the expression of an anti-apoptotic gene in a cell.
REFERENCES:
patent: 4868116 (1989-09-01), Morgan et al.
patent: 4980286 (1990-12-01), Morgan et al.
patent: 5212295 (1993-05-01), Cook
patent: 5328470 (1994-07-01), Nabel et al.
patent: 5521302 (1996-05-01), Cook
patent: 5587361 (1996-12-01), Cook et al.
patent: 5712257 (1998-01-01), Carter
patent: 5998203 (1999-12-01), Matulic-Adamic et al.
patent: 6054299 (2000-04-01), Conrad
patent: 6127533 (2000-10-01), Cook et al.
patent: 6166197 (2000-12-01), Cook et al.
patent: 6271358 (2001-08-01), Manoharan et al.
patent: 6423489 (2002-07-01), Anderson et al.
patent: 6486299 (2002-11-01), Shimkets
patent: 6506559 (2003-01-01), Fire et al.
patent: 2002/0086356 (2002-07-01), Tushcl et al.
patent: 2002/0114784 (2002-08-01), Li et al.
patent: 2002/0123034 (2002-09-01), Canaani et al.
patent: 2002/0132346 (2002-09-01), Cibelli
patent: 2002/0162126 (2002-10-01), Beach et al.
patent: 2002/0173478 (2002-11-01), Gerwitz
patent: 2003/0027783 (2003-02-01), Zernicka-Goetz et al.
patent: 2003/0108923 (2003-06-01), Tuschl et al.
patent: 2003/0125281 (2003-07-01), Lewis et al.
patent: 2003/0143732 (2003-07-01), Fosnaugh et al.
patent: 2003/0148341 (2003-08-01), Sin et al.
patent: 2003/0157030 (2003-08-01), Davis et al.
patent: 2003/0176671 (2003-09-01), Reed et al.
patent: 2003/0180756 (2003-09-01), Shi et al.
patent: 2003/0190635 (2003-10-01), McSwiggen
patent: 2003/0198627 (2003-10-01), Arts et al.
patent: 2004/0001811 (2004-01-01), Kreutzer et al.
patent: 2004/0072779 (2004-04-01), Kreutzer et al.
patent: 199 56 568 (1999-01-01), None
patent: 196 18 797 (2000-03-01), None
patent: 1 144 623 (2002-08-01), None
patent: 1 230 375 (2005-07-01), None
patent: WO 89/02468 (1989-03-01), None
patent: WO 89/05345 (1989-06-01), None
patent: WO 89/07136 (1989-08-01), None
patent: WO 92/07573 (1992-05-01), None
patent: WO 92/19732 (1992-11-01), None
patent: WO 94/01550 (1994-01-01), None
patent: WO 98/05770 (1998-02-01), None
patent: WO 98/53083 (1998-11-01), None
patent: WO 99/15682 (1999-04-01), None
patent: WO 99/32619 (1999-07-01), None
patent: WO 99/19029 (1999-09-01), None
patent: WO 99/53050 (1999-10-01), None
patent: WO 99/54459 (1999-10-01), None
patent: WO 99/61631 (1999-12-01), None
patent: WO 00/01846 (2000-01-01), None
patent: WO 00/22113 (2000-04-01), None
patent: WO 00/22114 (2000-04-01), None
patent: WO 00/44495 (2000-08-01), None
patent: WO 00/44895 (2000-08-01), None
patent: WO 00/44914 (2000-08-01), None
patent: WO 00/63364 (2000-10-01), None
patent: WO 00/68374 (2000-11-01), None
patent: WO 01/18197 (2001-03-01), None
patent: WO 01/29058 (2001-04-01), None
patent: WO 01/36646 (2001-05-01), None
patent: WO 01/42443 (2001-06-01), None
patent: WO 01/48183 (2001-07-01), None
patent: WO 03/035083 (2003-05-01), None
patent: WO 03/035868 (2003-05-01), None
patent: WO 03/035869 (2003-05-01), None
patent: WO 03/035870 (2003-05-01), None
patent: WO 03/035876 (2003-05-01), None
patent: WO 03/070283 (2003-08-01), None
patent: WO 03/070750 (2003-08-01), None
patent: WO 03/070969 (2003-08-01), None
patent: WO 03/070972 (2003-08-01), None
patent: WO 03/074654 (2003-09-01), None
patent: WO 03/080794 (2003-10-01), None
patent: WO 03/080807 (2003-10-01), None
patent: 2004027030 (2004-04-01), None
patent: 2004045543 (2004-06-01), None
patent: WO 2004/065601 (2004-08-01), None
patent: WO 2005/012357 (2005-02-01), None
Elbashir et al., Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate, 2001, The EMBO Journal, vol. 20, No. 23, pp. 6877-6888.
Hammond et al., Post-Transcriptional Gene Silencing by Double-Stranded RNA. 2001, Nature Reviews, Genetics, vol. 2, pp. 110-119.
Ambros, “Dicing Up RNAs”Science293:811-813 (2001).
Aoki et al., “RNA Interference May be More Potent than Antisense RNA in Human Cancer Cell Lines”Clin. Exp. Pharm. Phys. 30:96-102 (2003).
Armentano et al., “Expression of human factor IX in rabbit hepatocytes by retrovirus-mediated gene transfer: Potential for gene therapy of hemophilia B”Proc. Natl. Acad. Sci. USA87:6141-6145 (1990).
Basbaum et al., “Focalized proteolysis: spatial and temporal regulation of extra cellular matrix degradation at the cell surface”Curr. Opin. Cell Biol. 8:731-738 (1996).
Bass, “Double-Stranded RNA as a Template for Gene Silencing”Cell101:235-238 (2000).
Beck, “Unknotting the Complexities of Multidrug Resistance: The Involvement of DNA Topoisomerases in Drug Action and Resistance”J. Natl. Cancer Inst. 81:1683-1685 (1989).
Berkner et al., “Development of Adenovirus Vectors for the Expression of Heterologous Genes”BioTechniques6(7):616-629 (1998).
Birkedal-Hansen et al., “Matrix Metalloproteinases: A Review”Crit. Rev.Oral Biol. Med. 4:197-250 (1993).
Boyd, “Invasion and metastasis”Cancer Metastasis Rev. 15(1):77-89 (1996).
Braasch et al., “Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA”Chem. Biol. 8:1-7 (2001).
Brinckerhoff et al., “Matrix metalloproteinases: a tail of a frog that became a prince”Nature Reviews3:207-214 (2002).
Bucchini et al., “Pancreatic Expression of Human Insulin Gene in Transgenic Mice”PNAS USA83:2511-2515 (1986).
Caplen et al., “Specific Inhibition of Gene Expression by Small Double-Stranded RNAs in Invertebrate and Vertebrate Systems”PNAS USA98(17):9742-9747 (2001).
Caplen, “A New Approach to the Inhibition of Gene Expression”Trends in Biotech. 20(2):49-51 (2002).
Chao et al., “BCL-2 Family: Regulators of Cell Death”Annu. Rev. Immunol. 16:395-419 (1998).
Chen et al., “Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo”Proc. Natl. Acad. Sci. USA91:3054-3057 (1994).
Childs et al., “The MDR Superfamily of Genes and Its Biological Implications”Imp. Adv. Oncol. 21-36 (1994).
Chowdhury et al., “Long-Term Improvement of Hypercholesterolemia After Ex Vivo Gene Therapy in LDLR-Deficient Rabbits”Science254:1802-1805 (1991).
Cioca et al., “RNA interference is a functional pathway with therapeutic potential in human myeloid leukemia cell lines”Cancer Gene Therapy10:125-133 (2003).
Cobaleda et al., “In vivo inhibition by a site-specific catalytic RNA subunit of Rnase P designed against the BCR-ABL oncogenic products: a novel approach for cancer treatment”Blood95(3):731-737 (2000).
Cole et al., “Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line”Science258:1650-1654 (1992).
Cornetta et al., “Safety Issues Related to Retroviral-Mediated Gene Transfer in Humans”Human Gene Therapy2 (1):5-10 (1991).
Cone et al., “High-efficiency gene transfer into mammalian cells: Generation of helper-free recombinant retrovirus with broad mammalian host range”Proc. Natl. Acad. Sci. USA81:6349-6353 (1984).
Cook, “Medicinal chemistry of antisense oligonucleotides—future opportunities”Anti-Cancer Drug Design6:585-607 (1991).
Couture et al., “Anti-gene therapy: the use of ribozymes to inhibit gene function”Trends in Genetics12(12):510-515 (1996).
Crooke et al., “Pharmacokinetic Properties of Several Novel Oligonucleotide Analogs in Mice”J. Pharmacol. Exp. Ther. 277:923 (1996).
Dai et al., ȁ
Alnylam Pharmaceuticals, Inc.
Angell J. E.
Bowman Amy H.
Lowrie Lando & Anastasi, LLP
LandOfFree
Compositions and methods for inhibiting expression of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for inhibiting expression of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for inhibiting expression of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3990755